TCM
Tekla Capital Management Portfolio holdings
AUM
$2.56B
1-Year Return
18.15%
This Quarter Return
+13.63%
1 Year Return
+18.15%
3 Year Return
+62.34%
5 Year Return
+140.22%
10 Year Return
+499.57%
AUM
$2.76B
AUM Growth
+$122M
(+4.6%)
Cap. Flow
-$186M
Cap. Flow
% of AUM
-6.75%
Top 10 Holdings %
Top 10 Hldgs %
38.62%
Holding
217
New
37
Increased
33
Reduced
47
Closed
5
Top Buys
| 1 |
Zoetis
ZTS
|
$17.5M |
| 2 |
Johnson & Johnson
JNJ
|
$14.4M |
| 3 |
Elevance Health
ELV
|
$8.36M |
| 4 |
Novo Nordisk
NVO
|
$7.83M |
| 5 |
Thermo Fisher Scientific
TMO
|
$6.76M |
Top Sells
| 1 |
Merck
MRK
|
$45.3M |
| 2 |
Pfizer
PFE
|
$44.3M |
| 3 |
Vertex Pharmaceuticals
VRTX
|
$33.4M |
| 4 |
UnitedHealth
UNH
|
$21.5M |
| 5 |
Eli Lilly
LLY
|
$18.6M |
Sector Composition
| 1 | Healthcare | 93.74% |
| 2 | Real Estate | 2.75% |
| 3 | Financials | 0.62% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
BLUE
51
DELISTED
bluebird bio
BLUE
| $12.8M | 0.46% |
6,777
+1,203
| +22% | +$2.28M |
|
52
SPDR S&P Biotech ETF
XBI
$5.39B
| $12.4M | 0.45% |
129,000
-121,460
| -48% | -$11.6M |
|
|
AMRN
53
Amarin Corp
AMRN
$317M
| $12.3M | 0.44% |
37,702
+13,795
| +58% | +$4.49M |
|
|
PVLA
54
Palvella Therapeutics, Inc. Common Stock
PVLA
$616M
| $11.7M | 0.42% |
26,092
| – | – |
|
|
BPMC
55
DELISTED
Blueprint Medicines
BPMC
| $11.4M | 0.41% |
146,001
| – | – |
|
|
DHC
56
Diversified Healthcare Trust
DHC
$995M
| $11.4M | 0.41% |
646,554
| – | – |
|
57
Baxter International
BAX
$12.5B
| $11.3M | 0.41% |
146,040
+11,916
| +9% | +$919K |
|
58
Galapagos
GLPG
$2.2B
| $11.2M | 0.41% |
99,815
+13,000
| +15% | +$1.46M |
|
59
Alnylam Pharmaceuticals
ALNY
$59.2B
| $11M | 0.4% |
126,176
-4,200
| -3% | -$368K |
|
60
McKesson
MCK
$85.5B
| $11M | 0.4% |
82,947
-15,850
| -16% | -$2.1M |
|
61
FibroGen
FGEN
$48.9M
| $10.8M | 0.39% |
7,128
| – | – |
|
62
Amicus Therapeutics
FOLD
$2.46B
| $10.6M | 0.38% |
875,304
| – | – |
|
63
HCA Healthcare
HCA
$98.5B
| $10.3M | 0.38% |
74,335
-755
| -1% | -$105K |
|
64
Cencora
COR
$56.7B
| $10.3M | 0.37% |
111,807
+19,100
| +21% | +$1.76M |
|
65
Exelixis
EXEL
$10.2B
| $9.82M | 0.36% |
553,940
+125,918
| +29% | +$2.23M |
|
|
XLRN
66
DELISTED
Acceleron Pharma Inc.
XLRN
| $9.77M | 0.35% |
170,766
| – | – |
|
67
Acadia Healthcare
ACHC
$2.19B
| $9.59M | 0.35% |
272,400
| – | – |
|
|
LTC
68
LTC Properties
LTC
$1.69B
| $9.25M | 0.34% |
209,673
| – | – |
|
69
GSK
GSK
$81.5B
| $8.79M | 0.32% |
174,960
-112,240
| -39% | -$5.64M |
|
|
DPLO
70
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
| $8.52M | 0.31% |
439,001
| – | – |
|
71
Cigna
CI
$81.5B
| $8.43M | 0.31% |
40,461
| – | – |
|
72
Esperion Therapeutics
ESPR
$540M
| $8.4M | 0.3% |
189,287
| – | – |
|
73
Merus
MRUS
$5.1B
| $8.18M | 0.3% |
414,115
| – | – |
|
74
Sanofi
SNY
$113B
| $8.04M | 0.29% |
179,900
| – | – |
|
75
CRISPR Therapeutics
CRSP
$4.99B
| $7.91M | 0.29% |
178,348
| – | – |
|